Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas
暂无分享,去创建一个
[1] R. Arceci,et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. , 2010, Blood.
[2] C. Flowers,et al. Racial Disparities in Disease Presentation, Treatment, and Response Rates of Follicular Lymphoma (FL) in the United States (US): Report From the National LymphoCare Study (NLCS). , 2009 .
[3] H. Heslop,et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. , 2009, Blood.
[4] E. Riedel,et al. Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Cerhan,et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Daphne de Jong,et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols , 2009, Haematologica.
[7] Hao Liu,et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.
[8] J. Friedberg,et al. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. , 2008, Seminars in hematology.
[9] H. Heslop,et al. Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor , 2008, Journal of immunotherapy.
[10] E. Riedel,et al. Psychosocial functioning in survivors of Hodgkin lymphoma (HL) treated during adulthood , 2008 .
[11] Yu-Hong Chen,et al. Modified Donor Lymphocyte Infusion (DLI) for the Prophylaxis of Leukemia Relapse after Hematopoietic Stem Cell Transplantation in Patients with Advanced Leukemia—Feasibility and Safety Study , 2008, Journal of Clinical Immunology.
[12] A. Zelenetz,et al. Overview of lymphoma diagnosis and management. , 2008, Radiologic clinics of North America.
[13] V. Diehl,et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). , 2008, Blood.
[14] A. Zelenetz,et al. Practice Patterns in the Diagnosis of Follicular Lymphoma (FL): Report from the National Lymphocare Study (NLCS). , 2007 .
[15] Chung-Che Chang,et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. , 2007, Blood.
[16] M. Calaminici,et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Schwarzer,et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.
[18] A. Hart,et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. , 2007, Blood.
[19] Philip M Kluin,et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Salles. Clinical features, prognosis and treatment of follicular lymphoma. , 2007, Hematology. American Society of Hematology. Education Program.
[21] Marylène Lejeune,et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Heslop,et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.
[23] Max Wolf,et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.
[24] M. Calaminici,et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Emili Montserrat,et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.
[26] R. Gascoyne,et al. The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Fosså,et al. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. , 2006, European journal of cancer.
[28] R. Fisher,et al. New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Marcus,et al. Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up. , 2005 .
[30] Karey Shumansky,et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.
[31] L. Wildt,et al. Female fertility after cytotoxic therapy – protection of ovarian function during chemotherapy of malignant and non‐malignant diseases , 2005, European journal of haematology. Supplementum.
[32] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[33] V. Diehl,et al. Current treatment and immunotherapy of Hodgkin's lymphoma. , 2005, Haematologica.
[34] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[35] A. Zelenetz,et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.
[36] E. Alba,et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.
[38] R. Gascoyne,et al. Long‐term disease‐free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation , 2004, British journal of haematology.
[39] Ruta Bajorunaite,et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.
[40] H. Bartelink,et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] K. Maclennan,et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.
[42] J. Massagué,et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. , 2002, Blood.
[43] V. Diehl,et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] J. Lou. The Stedman's Concise Medical Dictionary , 2000 .
[45] G. Denardo,et al. A new era for radiolabeled antibodies in cancer? , 1999, Current opinion in immunology.
[46] A. Lennard,et al. Management of non-Hodgkin's lymphomas , 1999, Postgraduate medical journal.
[47] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] H. Tilly,et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Koziol,et al. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. , 1995, Blood.
[50] S. Horning. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.
[51] T. Kuzel,et al. Radioimmunotherapy of lymphoma. , 1993, Cancer treatment and research.
[52] A. Saven,et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Horning,et al. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.